

LA JOLLA PHARMACEUTICAL CO

Form 424B3

May 07, 2002

**TABLE OF CONTENTS**

**SELLING STOCKHOLDERS**

---

**Table of Contents**

Filed Pursuant to Rule 424(b)(3)  
 Registration Statement No. 333-81432

**Prospectus Supplement No. 1**  
**to**  
**Prospectus Dated February 4, 2002**

**LA JOLLA PHARMACEUTICAL COMPANY**

**Common Stock**

The following information supplements, and must be read in connection with, the information contained in the Prospectus, dated February 4, 2002 (the Prospectus), of La Jolla Pharmaceutical Company, a Delaware corporation. This Prospectus Supplement must be delivered with a copy of the Prospectus. All capitalized terms not otherwise defined herein have the respective meanings ascribed to them in the Prospectus.

The following information replaces in its entirety the information provided in the Prospectus under the caption Selling Stockholders.

**SELLING STOCKHOLDERS**

In a series of private transactions completed on January 17, 2002, we issued a total of 7,000,000 shares of our common stock to the stockholders listed below. The selling stockholders may from time to time offer and sell pursuant to this prospectus any or all of 7,000,000 shares of our common stock. The following table describes, as of May 7, 2002, the number of shares of our common stock that each selling stockholder beneficially owns and the number of shares registered hereunder. The term selling stockholders includes the holders listed below and their transferees, pledgees, donees or other successors. We have prepared this table based upon information furnished to us by or on behalf of the selling stockholders.

The selling stockholders confirmed at the time they acquired the shares listed below that they acquired the shares for investment purposes only and not with a view toward their resale, and acknowledged the existence of restrictions on resale that apply to these shares. This offering relates only to the sale of the 7,000,000 shares of common stock held or to be held by the selling stockholders named in the following table. Since the date on which they provided us with the information below, the selling stockholders may have sold, transferred or otherwise disposed of some or all of their shares of our common stock in transactions exempt from the registration requirements of the Securities Act.

Name of Selling Stockholder	Shares of Common Stock Owned Prior to Offering		Shares of Common Stock Owned After Offering	
	Number of Shares	Percent of Class(%) <sup>(1)</sup>	Number of Shares Sold <sup>(2)</sup>	Percent of Class(%) <sup>(2)</sup>
SAFECO Growth Opportunities Fund				
A series of SAFECO Common Stock Trust	1,216,000	2.9	1,216,000	
Deka-Team-Biotech (3)	1,019,009	2.4	484,450	534,559 1.3
Deerfield Partners, L.P.	746,936	1.8	139,750	607,186 1.4
Deerfield International Limited	589,264	1.4	110,250	479,014 1.1
Growth Opportunities Fund				
A series of SAFECO Resource Series Trust	584,000	1.4	584,000	
Brookside Capital Partners Fund, L.P.	500,000	1.2	500,000	
SEI Institutional Managed Trust	344,800	*	318,500	26,300 *
Compound Capital Growth Partners, Ltd.	320,294	*	320,294	

**Table of Contents**

Name of Selling Stockholder	Shares of Common Stock Owned Prior to Offering			Shares of Common Stock Owned After Offering	
	Number of Shares	Percent of Class(1)	Shares to be Sold(2)	Number of Shares(2)	Percent of Class(2)
EGS Private Healthcare Partnership II, L.P.	303,085	*	303,085		
Special Situations Fund III, L.P.	285,000	*	285,000		
SEI Institutional Investments Trust	257,200	*	237,200	20,000	*
Zeke, LP	225,000	*	225,000		
RS Smaller Company Growth Fund	210,600	*	75,000	135,600	*
SF Capital Partners, LTD	200,000	*	200,000		
JP Morgan U.S. Small Company Fund	170,750	*	28,350	142,400	*
Compound Capital Growth Partners II, LP	153,900	*	153,900		
Utah Retirement Systems	141,000	*	130,100	10,900	*
Special Situations Private Equity Fund, L.P.	125,000	*	125,000		
Anvers Healthcare Investors, LP	124,000	*	63,000	61,000	*
Pierpont Small Company Opportunities Fund	121,932	*	20,600	101,332	*
CCGrowth Global Life Sciences Ltd.	122,573	*	106,614	15,959	*
UBS Global Equity Arbitrage Master Limited	100,000	*	100,000		
O Connor PIPES Corporate Strategies Ltd.	100,000	*	100,000		
Special Situations Cayman Fund, L.P.	90,000	*	90,000		
JPMCB U.S. Small Company Equity I Growth	84,200	*	13,175	71,025	*
G. Nicholas Farwell(4)	75,000	*	75,000		
CCGrowth Global Life Sciences I, LP	58,097	*	58,097		*
RS Orphan Fund, L.P.	70,000	*	70,000		
Compound Capital Growth Partners III, LP	68,073	*	68,073		
Ivory Opportunity Fund, LP	67,500	*	67,500		
JPM Tax Aware Small Company Opportunities Fund	67,361	*	14,200	53,161	*
Daughters of Charity Fund P	61,900	*	57,100	4,800	*
Undiscovered Managers Small Cap Growth Fund	61,100	*	56,200	4,900	*
Compound Capital Growth Partnership, LP	50,799	*	50,799		
AIG DKR Soundshore Holdings Ltd.	50,000	*	50,000		
EGS Private Healthcare Investors II, L.P.	47,800	*	47,800		
EGS Private Healthcare Canadian Partners, L.P.	45,607	*	45,607		
Vision Small Cap Stock Fund	39,100	*	36,100	3,000	*
Alfred I. Dupont Testamentary Trust	33,300	*	30,700	2,600	*
Ivory Opportunity Fund, Ltd.	32,500	*	32,500		
Les Schwab P/S Retirement Trust	30,300	*	28,000	2,300	*
RS Orphan Offshore Fund, L.P.	30,000	*	30,000		
CCGrowth Global Life Sciences II, LP	35,741	*	30,954	4,787	*
East Bay Municipal Utility District	25,900	*	23,900	2,000	*
Met. Inv. Tr Small Cap Stock SSB	25,425	*	3,925	21,500	*
The Paisley Fund, LP	25,000	*	25,000		
JP Morgan Global Healthcare Fund(3)	22,709	*	3,850	18,859	*
Anvers Healthcare Investors International, Ltd.	22,700	*	12,000	10,700	*
Philips Pensionfondsen-Small Cap	22,225	*	3,725	18,500	*
Maximus Managed Offshore, Ltd.	21,340	*	21,340		
Ret. Pl. For Union Carbide Corp.	20,029	*	3,800	16,229	*
Maximus Capital Investments, Ltd.	18,870	*	18,870		
Westfield Life Sciences Fund LP	15,900	*	15,900		
JPM Global Healthtech Fund(3)	15,500	*	15,500		
JPMCB U.S. Small Company Equity II Growth	15,475	*	2,650	12,825	*
Memorial Hospital of South Bend, Inc.	12,500	*	11,500	1,000	*
PGH Pension	11,600	*	10,700	900	*
DSM NV PENS VERZ MIJ-Small Cap	11,025	*	1,825	9,200	*
JP Morgan Series Trust Small Company Growth Portfolio	10,825	*	2,125	8,700	*

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 424B3

Westfiled Life Sciences Fund LP II	9,100	*	9,100		
Nemours Foundation	8,000	*	7,400	600	*

2

---

**Table of Contents**

Name of Selling Stockholder	Shares of Common Stock Owned Prior to Offering			Shares of Common Stock Owned After Offering	
	Number of Shares	Percent of Class(%) <sup>(1)</sup>	Shares to be Sold <sup>(2)</sup>	Number of Shares <sup>(2)</sup>	Percent of Class(%) <sup>(2)</sup>
Caddis Master Fund Ltd.	6,934	*	6,934		
JP Morgan Diversified Fund	6,900	*	1,825	5,075	*
Maximus Managed Domestic, L.P.	5,090	*	5,090		
The Baetis Fund, LP	4,799	*	4,335	464	*
Maximus Capital, L.P.	4,700	*	4,700		
EGS Private Healthcare Presidents Fund, L.P.	3,508	*	3,508		
Wilshire U.S. Equity Fund	2,800	*	2,600	200	*

\* Less than 1%

(1) Computed based on 42,312,412 shares of common stock outstanding as of March 28, 2002.(2) Assumes all the shares of common stock that may be offered hereunder are sold.(3) Registered in the name of Cudd & Co.(4) 50,000 shares of common stock are held in the name of G. Nicholas Farwell and Gail M. Farwell JTWROS, and 25,000 shares of common stock are held in the name of G. Nicholas Farwell Sep. Pty.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 424B3

The information regarding the selling stockholders may change from time to time. If required, we will describe these changes in one or more prospectus supplements.

**The Date of This Prospectus Supplement Is May 7, 2002**